Tag Archives: HIVE

Hot Medical Stocks To Invest In Right Now

&l;p&g;Everyone wants to see Alzheimer&a;rsquo;s disease cured; and certainly theories abound regarding its cause and a potential cure. But what puzzles even more of us and concerns physicians and scientists alike are the host of products being sold that claim to prevent or treat memory loss without any hardcore old-fashioned science to back it up. In fact, the concern is so great that the Alzheimer&a;rsquo;s Association&a;mdash;the world&a;rsquo;s leading voluntary health organization in Alzheimer&s;s care, support and research&a;mdash;has compiled a &l;a href=&q;https://www.alz.org/alzheimers_disease_alternative_treatments.asp&q; target=&q;_blank&q;&g;list&l;/a&g; of these alternative medicines and the hard truth behind them.

They&a;rsquo;re everywhere. Herbal remedies, dietary supplements and &q;medical foods&q;&a;nbsp;being promoted as memory enhancers or treatments to delay or prevent Alzheimer&a;rsquo;s disease and &l;a href=&q;https://www.alz.org/dementia/types-of-dementia.asp&q; target=&q;_blank&q;&g;related dementias&l;/a&g;. But the Alzheimer&a;rsquo;s Association is reminding a desperate public that claims about the safety and effectiveness of these products are &a;ldquo;based largely on testimonials, traditionand a rather small body of scientific research.&a;rdquo;

Hot Medical Stocks To Invest In Right Now: Cracker Barrel Old Country Store Inc.(CBRL)

Advisors’ Opinion:

  • [By Asit Sharma]

    If you’ve driven on a highway in the South or Midwest, you’ve probably seen billboards for Cracker Barrel (NASDAQ:CBRL) — and that’s part of what makes Cracker Barrel such a compelling buy.

  • [By Motley Fool Staff]

    Cracker Barrel (NASDAQ:CBRL) has treated its shareholders with a huge dose of southern hospitality, as shares have gained 24% annually on a total return basis over the last five years. The organization’s relatively stable business model of attracting recurring restaurant visits from highway travelers, and enticing them to visit adjoining gift stores, implies a level of safety versus faster-growth companies. Still, red flags exist, and in the following segment from a recent Motley Fool Industry Focus podcast, we outline problem areas investors should be aware of.

  • [By Stephan Byrd]

    Waratah Capital Advisors Ltd. decreased its position in Cracker Barrel (NASDAQ:CBRL) by 94.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,675 shares of the restaurant operator’s stock after selling 45,017 shares during the quarter. Waratah Capital Advisors Ltd.’s holdings in Cracker Barrel were worth $426,000 at the end of the most recent reporting period.

Hot Medical Stocks To Invest In Right Now: Aerohive Networks, Inc.(HIVE)

Advisors’ Opinion:

  • [By Max Byerly]

    Leidos (NYSE: LDOS) and Aerohive Networks (NYSE:HIVE) are both aerospace companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

  • [By Logan Wallace]

    Aerohive Networks Inc (NYSE:HIVE) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 573,420 shares, a drop of 35.3% from the May 31st total of 885,671 shares. Based on an average trading volume of 381,201 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.8% of the shares of the stock are short sold.

  • [By ]

    Our Biggest Loser… And A Bunch Of Big Wins
    Our biggest loser was back in January when we closed out of small communications equipment firm Aerohive Networks (Nasdaq: HIVE). On January 17, the company made a statement about its upcoming fourth-quarter earnings release, warning that revenue would likely be near the lower end of its guidance range. Investors didn’t take kindly to the news and sent shares tumbling by roughly 30%… well below our 15% trailing stop-loss. We ended up closing out with a 35% loss on the trade.

  • [By Stephan Byrd]

    Here are some of the news articles that may have effected Accern’s rankings:

    Get Anthera Pharmaceuticals alerts:

    Cystic Fibrosis Drugs Market – Future Growth Prospects and Industry Trends Analyzed Till 2025 (digitaljournal.com) Analysts Anticipate Anthera Pharmaceuticals Inc (ANTH) Will Announce Earnings of -$0.60 Per Share (americanbankingnews.com) News Buzz : Blink Charging Co. (NASDAQ:BLNK), Genocea Biosciences, Inc. (NASDAQ:GNCA), Anthera … (journalfinance.net) Current Lumpy Stocks:: Jounce Therapeutics, Inc. (NASDAQ:JNCE), Aerohive Networks, Inc. (NYSE:HIVE), Anthera … (journalfinance.net) Porous, non-porous tantalum cups yielded similar septic, aseptic risks after revision THA (healio.com)

    ANTH has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Tuesday, February 13th. Jefferies Financial Group reiterated a “hold” rating and set a $0.50 target price on shares of Anthera Pharmaceuticals in a research report on Thursday, March 15th. Roth Capital initiated coverage on Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, Piper Jaffray Companies downgraded Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research report on Monday, March 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $3.44.

Hot Medical Stocks To Invest In Right Now: Village Super Market Inc.(VLGEA)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Media stories about Village Super Market, Inc. Class A (NASDAQ:VLGEA) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Village Super Market, Inc. Class A earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 43.9608995956738 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Logan Wallace]

    Village Super Market, Inc. Class A (NASDAQ: VLGEA) and Koninklijke Ahold (OTCMKTS:ADRNY) are both retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

  • [By Ethan Ryder]

    BidaskClub lowered shares of Village Super Market (NASDAQ:VLGEA) from a hold rating to a sell rating in a report published on Tuesday.

    Shares of VLGEA stock opened at $27.20 on Tuesday. Village Super Market has a 52-week low of $21.95 and a 52-week high of $31.49. The company has a quick ratio of 1.38, a current ratio of 1.81 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $392.70 million, a price-to-earnings ratio of 13.80 and a beta of 0.04.

  • [By Shane Hupp]

    BidaskClub upgraded shares of Village Super Market (NASDAQ:VLGEA) from a sell rating to a hold rating in a research report report published on Tuesday.

Hot Medical Stocks To Invest In Right Now: OncoCyte Corporation(OCX)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares surged 144.96 percent to close at $265.61 on Thursday in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) shares rose 101.01 percent to close at $9.99 on Thursday after falling 4.42 percent on Wednesday.
    Akers Biosciences, Inc. (NASDAQ: AKER) jumped 45.58 percent to close at $0.474. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days.
    Kitov Pharma Ltd (NASDAQ: KTOV) gained 40.93 percent to close at $3.03 after the FDA approved Kitov's Consensi for the treatment of osteoarthritis pain and hypertension.
    China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 28.21 percent to close at $19.86.
    J.Jill, Inc. (NYSE: JILL) climbed 26.45 percent to close at $7.84 after the company posted upbeat quarterly earnings.
    Curis, Inc. (NASDAQ: CRIS) shares climbed 21.93 percent to close at $2.78 in reaction to an encouraging FDA update. The biotechnology company that focuses on therapies for the treatment of cancer said the FDA granted a Fast Track designation for fimepinostat (CUDC-907) in patients with relapsed or refractory.
    Boxlight Corporation (NASDAQ: BOXL) gained 21.23 percent to close at $7.48.
    Kirkland's, Inc. (NASDAQ: KIRK) rose 16.21 percent to close at $12.83 after reporting upbeat Q1 results.
    The Brink's Company (NYSE: BCO) jumped 16.2 percent to close at $79.25 as the company announced plans to acquire Dunbar Armored for $520 million in cash.
    Applied Optoelectronics, Inc. (NASDAQ: AAOI) rose 15.14 percent to c
  • [By Jon C. Ogg]

    OncoCyte Corp. (NYSE: OCX) was started as Overweight with a $6 price target (versus a $3.84 close) at Piper Jaffray. It has a 52-week range of $1.10 to $6.92 and a market cap of only $191 million.

  • [By Money Morning News Team]

    You only have to review the one-week gains of some of the top penny stocks to see how much investors can benefit. The top performer recently, OncoCyte Corp. (NYSE: OCX), skyrocketed almost 160% on the week. Yet it can still be purchased at only $4.98 per share.

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

  • [By Money Morning Staff Reports]

    Just look at last week’s big winner, OncoCyte Corp. (NYSE: OCX). The stock surged nearly 160% in less than a week, and it still trades for just $4.98 a share.

Best High Tech Stocks For 2019

LISTEN TO ARTICLE 2:16 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

Bahrain and its Gulf Arab allies are said to be making progress on an aid program to help the island-kingdom repair its finances and avoid a devaluation that could roil neighboring markets.

Officials from Bahrain, Saudi Arabia, the United Arab Emirates and Kuwait are discussing a multi-year program that would involve spending cuts and measures to increase non-oil revenue, including the introduction of a value-added tax, according to five people with knowledge of the matter. They asked not to be identified because the details aren’t public.

Best High Tech Stocks For 2019: Starbucks Corporation(SBUX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Starbucks Corp. (NYSE: SBUX) fell about 1.1% Tuesday to post a new 52-week low of $50.11. Shares closed at $50.66 on Monday. The 52-week high is $61.94. Volume of around 10 million was about 3% higher than the daily average. The company had no specific news but a rival chain is stepping in to open new stores.

  • [By Billy Duberstein]

    After stagnating over the course of two and half years, Starbucks (NASDAQ:SBUX) stock is showing signs of perking up. In fact, since its summer swoon, better-than-expected earnings have catapulted shares a handsome 40% off their July 2018 lows.

  • [By Douglas A. McIntyre]

    Starbucks Corp. (NASDAQ: SBUX) has a new benefit for employees: child and adult care support. With a company called Care.com, it will start a new program. And the prices to Starbucks employees will be very low.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Starbucks (SBUX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Daniel B. Kline]

    Visit nearly any Starbucks (NASDAQ:SBUX) at almost any time of day, and you’ll see proof that the company has succeeded in its goal of becoming a “third place” — a social center beyond the home or the workplace. Its tables may be occupied by people working on novels, groups of friends chatting, businesspeople conducting meetings, and maybe even couples on dates.

  • [By Max Byerly]

    Gabelli Funds LLC raised its holdings in Starbucks (NASDAQ:SBUX) by 33.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 433,317 shares of the coffee company’s stock after acquiring an additional 109,000 shares during the quarter. Gabelli Funds LLC’s holdings in Starbucks were worth $25,085,000 as of its most recent filing with the Securities and Exchange Commission.

Best High Tech Stocks For 2019: Aerohive Networks, Inc.(HIVE)

Advisors’ Opinion:

  • [By Max Byerly]

    Leidos (NYSE: LDOS) and Aerohive Networks (NYSE:HIVE) are both aerospace companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

  • [By Stephan Byrd]

    Here are some of the news articles that may have effected Accern’s rankings:

    Get Anthera Pharmaceuticals alerts:

    Cystic Fibrosis Drugs Market – Future Growth Prospects and Industry Trends Analyzed Till 2025 (digitaljournal.com) Analysts Anticipate Anthera Pharmaceuticals Inc (ANTH) Will Announce Earnings of -$0.60 Per Share (americanbankingnews.com) News Buzz : Blink Charging Co. (NASDAQ:BLNK), Genocea Biosciences, Inc. (NASDAQ:GNCA), Anthera … (journalfinance.net) Current Lumpy Stocks:: Jounce Therapeutics, Inc. (NASDAQ:JNCE), Aerohive Networks, Inc. (NYSE:HIVE), Anthera … (journalfinance.net) Porous, non-porous tantalum cups yielded similar septic, aseptic risks after revision THA (healio.com)

    ANTH has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Tuesday, February 13th. Jefferies Financial Group reiterated a “hold” rating and set a $0.50 target price on shares of Anthera Pharmaceuticals in a research report on Thursday, March 15th. Roth Capital initiated coverage on Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, Piper Jaffray Companies downgraded Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research report on Monday, March 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $3.44.

  • [By Logan Wallace]

    Aerohive Networks Inc (NYSE:HIVE) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 573,420 shares, a drop of 35.3% from the May 31st total of 885,671 shares. Based on an average trading volume of 381,201 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.8% of the shares of the stock are short sold.

  • [By ]

    Our Biggest Loser… And A Bunch Of Big Wins
    Our biggest loser was back in January when we closed out of small communications equipment firm Aerohive Networks (Nasdaq: HIVE). On January 17, the company made a statement about its upcoming fourth-quarter earnings release, warning that revenue would likely be near the lower end of its guidance range. Investors didn’t take kindly to the news and sent shares tumbling by roughly 30%… well below our 15% trailing stop-loss. We ended up closing out with a 35% loss on the trade.

Best High Tech Stocks For 2019: Lexicon Pharmaceuticals, Inc.(LXRX)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Aperio Group LLC increased its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 49.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 19,270 shares of the biopharmaceutical company’s stock after buying an additional 6,377 shares during the period. Aperio Group LLC’s holdings in Lexicon Pharmaceuticals were worth $165,000 as of its most recent SEC filing.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    Sanofi’s also awaiting an FDA decision on sotagliflozin, a drug it licensed from Lexicon Pharmaceuticals (NASDAQ:LXRX) in 2015 for $300 million up front, up to $430 million in development and regulatory milestones, up to $990 million in specified sales milestones, and tiered, escalating royalties ranging from low double-digit percentages to 40% of net sales. 

  • [By Chris Lange]

    Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is making presentations at the American Diabetes Association on June 22 to 26. Lexicon recently traded at $13.58 a share, with a consensus analyst price target of $23.00 and a 52-week trading range of $7.67 to $18.00.

  • [By Keith Speights]

    Dividend Yield

    Abbott Laboratories (NYSE:ABT) Drugs $109 billion 19.37 1.88%
    AstraZeneca (NYSE: AZN) Drugs $93 billion 19.70 3.97%
    Becton Dickinson and Co. (NYSE: BDX) Medical supplies $60 billion 17.74 1.29%
    DexCom (NASDAQ: DXCM) Medical devices $8 billion N/A N/A
    Eli Lilly and Co. (NYSE: LLY) Drugs $85 billion 14.91 2.77%
    Insulet (NASDAQ: PODD) Medical devices $5 billion 273.03 N/A
    Johnson & Johnson (NYSE: JNJ) Drugs, medical devices $325 billion 14.16 2.57%
    Lexicon Pharmaceuticals (NASDAQ:LXRX) Drugs $1 billion N/A N/A
    MannKind (NASDAQ: MNKD) Drugs $270 million N/A N/A
    Medtronic (NYSE: MDT) Medical devices $117 billion 15.36 2.14%
    Merck & Co. (NYSE: MRK) Drugs $159 billion 12.99 3.22%
    Novo Nordisk (NYSE:NVO) Drugs $116 billion 18.29 2.61%
    Pfizer (NYSE: PFE) Drugs $209 billion 11.62 3.82%
    Regeneron Pharmaceuticals (NASDAQ: REGN) Drugs $32 billion 13.95 N/A
    Sanofi (NYSE: SNY) Drugs $95 billion 10.75 4.64%
    Senseonics Holdings (NYSEMKT: SENS) Medical devices $447 million N/A N/A
    Tandem Diabetes Care (NASDAQ: TNDM) Medical devices $711 million N/A N/A

    Data source: Yahoo! Finance. P/E = price-to-earnings ratio; N/A = not applicable. Data as of May 25, 2018.

Best High Tech Stocks For 2019: NeoGenomics, Inc.(NEO)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on NeoGenomics (NEO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    NEO (CURRENCY:NEO) traded up 3.5% against the dollar during the 1-day period ending at 16:00 PM Eastern on October 8th. NEO has a market capitalization of $1.21 billion and $161.27 million worth of NEO was traded on exchanges in the last day. One NEO coin can currently be purchased for approximately $18.64 or 0.00280368 BTC on major cryptocurrency exchanges including LBank, ZB.COM, Gate.io and Allcoin. In the last seven days, NEO has traded up 0.6% against the dollar.

  • [By Joseph Griffin]

    These are some of the media stories that may have effected Accern’s analysis:

    Get NeoGenomics alerts:

    NeoGenomics (NEO) Receives Buy Rating from Stephens (americanbankingnews.com) NeoGenomics Redeems 100% of Series A Redeemable Preferred Stock (finance.yahoo.com) Q2 2018 EPS Estimates for NeoGenomics, Inc. Cut by William Blair (NEO) (americanbankingnews.com) NeoGenomics (NEO) Receives Buy Rating from BTIG Research (americanbankingnews.com) Steven C. Jones Sells 2,000 Shares of NeoGenomics, Inc. (NEO) Stock (americanbankingnews.com)

    NeoGenomics traded up $0.40, hitting $13.90, during trading on Tuesday, MarketBeat Ratings reports. 6,150 shares of the company’s stock traded hands, compared to its average volume of 498,468. NeoGenomics has a 52 week low of $7.08 and a 52 week high of $14.18. The company has a quick ratio of 1.85, a current ratio of 2.03 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $1.13 billion, a P/E ratio of 231.50, a price-to-earnings-growth ratio of 6.69 and a beta of 0.48.

  • [By Ethan Ryder]

    BidaskClub lowered shares of NeoGenomics (NASDAQ:NEO) from a strong-buy rating to a buy rating in a research note published on Wednesday.

    Several other equities research analysts have also weighed in on the company. Leerink Swann began coverage on NeoGenomics in a report on Tuesday, August 21st. They issued an outperform rating and a $18.00 price objective for the company. Zacks Investment Research lowered NeoGenomics from a hold rating to a sell rating in a report on Thursday, July 19th. First Analysis set a $16.00 target price on NeoGenomics and gave the company a buy rating in a report on Tuesday, September 18th. BTIG Research reaffirmed a buy rating and set a $15.00 target price on shares of NeoGenomics in a report on Thursday, June 21st. Finally, Stephens reaffirmed a buy rating and set a $15.00 target price on shares of NeoGenomics in a report on Tuesday, June 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $19.25.

Best High Tech Stocks For 2019: Tesla Motors, Inc.(TSLA)

Advisors’ Opinion:

  • [By John Rosevear]

    This is an important deal. Tesla’s (NASDAQ:TSLA) Supercharger network has given it a big advantage in winning buyers away from internal-combustion alternatives. Any company looking to challenge Tesla will be at a disadvantage unless it can also provide its buyers with assurance that they’ll be able to access high-speed chargers on road trips. 

  • [By ]

    The solution to this problem — that is, night — is to build huge batteries, something that so far has been a real challenge. Right now, Tesla (Nasdaq: TSLA) has the world’s largest battery, a 100-megawatt beauty in Australia, about the size of a U.S. football field. That makes for a lot o’ juice. Enough, in fact, to power 30,000 homes.

  • [By John Rosevear]

    General Motors (NYSE:GM) and Honda Motor (NYSE:HMC) announced that they plan to team up on advanced batteries for electric vehicles in a bid to push back against Tesla (NASDAQ:TSLA) and its massive Gigafactory.

  • [By Rich Smith]

    I dusted off my crystal ball earlier this year and made three (I thought not very) bold predictions about what investors could expect from Tesla (NASDAQ:TSLA) stock in 2018. As we approach the midpoint mark of the year, however, it looks like I’m batting only .333:

Best High Tech Stocks For 2019: OraSure Technologies, Inc.(OSUR)

Advisors’ Opinion:

  • [By Shane Hupp]

    Integra Lifesciences (NASDAQ: OSUR) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) have been given an average rating of “Buy” by the seven research firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $20.00.

  • [By Max Byerly]

    SurModics (NASDAQ: OSUR) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Top Medical Stocks To Own Right Now

5 Lessons From the Life of David Noble

DOL Fiduciary Rule Hurts Now, Annuity Community Says

5 Lessons From the Life of David Noble

(Bloomberg) — The Trump White House and congressional Republicans were at odds Thursday over whether to try for another vote on changing the Affordable Care Act next week, indicating that neither side had a clear strategy for moving on one of the president’s central campaign promises.

A White House aide said President Donald Trump’s administration expects the House to vote soon after lawmakers return from recess on Tuesday, and draft language could be circulated as soon as Thursday night. Success would give the president a legislative victory to boast about before his 100th day in office April 29.

Copyright 2017 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

One Republican said he thinks both about the effects of regulations and his family’s medical history.

Top Medical Stocks To Own Right Now: Richmont Mines, Inc.(RIC)

Advisors’ Opinion:

  • [By Sally Jones]

    Richmont Mines Inc. (RIC)

    Down 70% over 12 months, Richmont Mines Inc. has a market cap of $56.23 billion, and trades with a P/B of 0.60.

Top Medical Stocks To Own Right Now: CytRx Corporation(CYTR)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.

    If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.

    Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.

    Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Medical Stocks To Own Right Now: Aerohive Networks, Inc.(HIVE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Aerohive Networks Inc (NYSE: HIVE) were down 33 percent to $3.10. Aerohive Networks reported a Q2 loss of $3.9 million on revenue of $42.3 million, and disclosed that it has extended its $10 million buyback plan.

  • [By Monica Gerson]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.16 per share on revenue of $17.34 billion before the opening bell. Citigroup shares rose 0.47 percent to $48.70 in after-hours trading.
    HP Inc (NYSE: HPQ) disclosed that it would be implementing a restructuring plan that would likely result in the firing of 3,000 to 4,000 employees, annual savings of $200 million to $300 million, and a charge of $350 million to $500 million. Management also announced a 7 percent surge in the stock’s dividend and an additional $3 million share repurchase program. The company issued its outlook for fiscal 2017, guiding for EPS of $1.55 to $1.65, mostly below the Street’s consensus of $1.64. HP shares fell 1.32 percent to $14.95 in the after-hours trading session.
    Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.39 per share on revenue of $23.99 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.37 perecent to $67.99 in after-hours trading.
    Aerohive Networks Inc (NYSE: HIVE) reported weak preliminary results for its third quarter. The company said it expects a net loss of $(0.06) to $(0.07) per share, versus consensus at $(0.04) per share. Revenue guidance of $40 million also fell short of expectations for almost $48 million. Aerohive shares dropped 18.29 percent to $4.60 in the after-hours trading session.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Top 10 Blue Chip Stocks To Own For 2018

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; text-align: justify; font: 13.0px Verdana; -webkit-text-stroke: #000000} span.s1 {font-kerning: none}

Dow 19,000 has a nice ring to it. And the iconic blue chip stock gauge is edging ever closer to that milestone.

After Mondays record-breaking day, when the Dow Jones industrial average, large-company Standard & Poors 500 stock index, tech-dominated Nasdaq composite and the small-cap Russell 2000 all closed at record levels at the same time for the first time since Dec. 31, 1999, the Dow is on the verge of making more headlines and getting a big shout outon the evening news.

.oembed-asset-link { border-bottom: 1px solid #e1e1e1; } .oembed-link-anchor { display: block; clear: both; } .oembed-link-thumbnail{ float: left; padding: 14px; } .oembed-link-thumbnail img { max-width: 78px; max-height: 60px; display: block; } p.oembed-link-title { font-size: 75%; color: #009BFF; margin: 0 14px; padding-top: 12px; font-weight:normal; text-align: left; line-height: 120%; } p.oembed-link-desc { font-size: 100%; color: #666; font-weight: normal; margin: 0 14px 14px 14px; font-family: ‘Futura Today Light’; text-align: left; line-height: 120%; }

USA TODAY

Top 10 Blue Chip Stocks To Own For 2018: Energy XXI Ltd.(EXXI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Energy XXI Ltd (NASDAQ: EXXI) were down 72 percent to $0.181 after the company announced that it and some of its subsidiaries have entered into a Restructuring Support Agreement (RSA) with holders of more than 63 percent of its secured second lien 11.0 percent notes. Energy XXI added that in order to implement the terms of the RSA, it has commenced cases under Chapter 11 of the Bankruptcy Code.

Top 10 Blue Chip Stocks To Own For 2018: Aerohive Networks, Inc.(HIVE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Aerohive Networks Inc (NYSE: HIVE) were down 33 percent to $3.10. Aerohive Networks reported a Q2 loss of $3.9 million on revenue of $42.3 million, and disclosed that it has extended its $10 million buyback plan.

  • [By Monica Gerson]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.16 per share on revenue of $17.34 billion before the opening bell. Citigroup shares rose 0.47 percent to $48.70 in after-hours trading.
    HP Inc (NYSE: HPQ) disclosed that it would be implementing a restructuring plan that would likely result in the firing of 3,000 to 4,000 employees, annual savings of $200 million to $300 million, and a charge of $350 million to $500 million. Management also announced a 7 percent surge in the stock’s dividend and an additional $3 million share repurchase program. The company issued its outlook for fiscal 2017, guiding for EPS of $1.55 to $1.65, mostly below the Street’s consensus of $1.64. HP shares fell 1.32 percent to $14.95 in the after-hours trading session.
    Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.39 per share on revenue of $23.99 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.37 perecent to $67.99 in after-hours trading.
    Aerohive Networks Inc (NYSE: HIVE) reported weak preliminary results for its third quarter. The company said it expects a net loss of $(0.06) to $(0.07) per share, versus consensus at $(0.04) per share. Revenue guidance of $40 million also fell short of expectations for almost $48 million. Aerohive shares dropped 18.29 percent to $4.60 in the after-hours trading session.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Top 10 Blue Chip Stocks To Own For 2018: Archer-Daniels-Midland Company(ADM)

Advisors’ Opinion:

  • [By Lee Jackson]

    This is a very solid play for rocky markets and is offering a very reasonable entry point. Archer Daniels Midland Co. (NYSE: ADM) is a large agricultural services company with almost $90 billion in sales. It is in the business of converting agricultural harvest such as corn, wheat, soybeans and other products into basic ingredients for both consumer and industrial product manufacturers. Its main business lines are focused on oilseed processing, corn processing and agricultural services.

  • [By WWW.MONEYSHOW.COM]

    Aflac (AFL) — yielding 2.5%
    Archer-Daniels Midland (ADM) — yielding 2.7%
    Chevron (CVX) — yielding 3.8%
    ExxonMobil (XOM) — yielding 3.6%
    Genuine Parts (GPC) — yielding 2.7%
    Johnson & Johnson (JNJ) — yielding 2.8%
    T. Rowe Price (TROW) — yielding 3.2%

Top 10 Blue Chip Stocks To Own For 2018: Citigroup Inc.(C)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    Earnings season will kick into high gear today with the release of multiple reports from three of the nation’s top financial institutions. JPMorgan Chase & Co. (NYSE: JPM), Wells Fargo & Co.(NYSE: WFC), and Citigroup Inc. (NYSE: C) will all be in the spotlight today. U.S. President Donald Trump could be shaking up trade policy. However, it isn’t NAFTA or tariffs with China that are headlining the story. According to reports, Trump has requested his advisors explore American reentry into the Transpacific Partnership (TPP). President Trump pulled the United States out of TPP shortly following his inauguration. The recommendation comes after lawmakers from ag-producing states discussed the impact of leaving the deal with the administration. The decision to reenter the TPP would be very valuable to states that produce the bulk of U.S. wheat given that it would allow exporters to avoid tariffs of $65 per tonne to Japan, which is the largest export market for American wheat. Leading nations of the pact, such as Japan and Australia, reacted coolly to the president’s pivot but did not rule out the possibility of American reentry. Facebook Inc. (Nasdaq: FB) is still in focus across the financial world. Facebook CEO Mark Zuckerberg appeared before Congress two times this week to address his firm’s ongoing data scandal involving consulting firm Cambridge Analytica. Congress’ failure to understand how the Internet works and Facebook’s business model was on full display, but Zuckerberg was able to maintain his composure as he answered questions over the two-day period.
    Stocks to Watch Today: JPM, WFC, C
    Shares of JPMorgan Chase & Co. (NYSE: JPM) are in focus as the bank prepares to report Q1 earnings before the bell. JPM stock added 1.1% despite falling short of profit expectations. Wall Street anticipated that the firm would report earnings per share (EPS) of $2.28 on top of $27.53 billion in revenue. The firm reported EPS of $2.26; however, it reported

  • [By WWW.THESTREET.COM]

    Some money managers are indeed preparing for Armageddon, expecting a thin summer trading season to usher in the bear. But Cramer said that, ultimately, what happens in Washington has little impact on the earnings of stocks like Walmart (WMT) , Coca-Cola (KO) or Citigroup (C) . It also has no correlation to the 17.8% move in Nvidia (NVDA) , nor the 12.8% jump in Electronic Arts (EA) .

  • [By ]

    Everything is hot, always: (1) Well-known bank analyst Mike Mayo told TheStreet’s Scott Gamm that former Goldman exec (and Trump exec) Gary Cohn would be a good person to replace Citigroup’s (C) chairman; (2) TheStreet’s May 5 “Investing Bootcamp” conference in New York is a MUST attend — here is just a small sampling of what we will be discussing; (3) TheStreet’s new “Retirement Daily’ service is now live. Led by long-time retirement expert, aka “Mr. Retirement” Robert Powell, this is an amazing service. Trust me, I get to view all the content before it goes live … there is nothing else like it out there. Check out more here; (4) RealMoney Pro’s long-time columnist and money manager Doug Kass hops out briefly from behind the paywall with a new daily column called Kass Insider. First installment: Why Facebook’s Stock Could Be ‘Dead Money’ for the Rest of 2018.

  • [By Shane Hupp]

    A number of institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. boosted its position in shares of Citigroup by 17.3% during the 3rd quarter. Principal Financial Group Inc. now owns 4,869,619 shares of the financial services provider’s stock worth $354,216,000 after purchasing an additional 717,320 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Citigroup by 17.0% during the 3rd quarter. Prudential Financial Inc. now owns 7,514,341 shares of the financial services provider’s stock worth $546,594,000 after purchasing an additional 1,092,980 shares in the last quarter. C WorldWide Group Holding A S boosted its position in shares of Citigroup by 13.1% during the 3rd quarter. C WorldWide Group Holding A S now owns 6,603,267 shares of the financial services provider’s stock worth $480,322,000 after purchasing an additional 764,249 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Citigroup by 3.7% during the 3rd quarter. Macquarie Group Ltd. now owns 363,594 shares of the financial services provider’s stock worth $26,448,000 after purchasing an additional 13,019 shares in the last quarter. Finally, Harvey Capital Management Inc. boosted its position in shares of Citigroup by 47.6% during the 3rd quarter. Harvey Capital Management Inc. now owns 124,635 shares of the financial services provider’s stock worth $9,065,000 after purchasing an additional 40,195 shares in the last quarter. 80.13% of the stock is currently owned by institutional investors and hedge funds.

    COPYRIGHT VIOLATION NOTICE: “Investors Sell Citigroup (C) on Strength (C)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & cop

Top 10 Blue Chip Stocks To Own For 2018: Wells Fargo & Company(WFC)

Advisors’ Opinion:

  • [By ]

    Gold. The rise in gold looks solid. I’m currently long the SPDR Gold Shares ETF (GLD) . Lackluster Banks. We’re seeing disappointing action in the financials. However, I continue to buy them. I’m long Bank of America (BAC) , Citigroup (C) , JPMorgan Chase (JPM) and Wells Fargo (WFC) , although I’m shorting Goldman Sachs (GS) .

    Lastly, with S&P 500 closing at 2,706, the downside risk relative to the upside reward seems to argue in favor of maintaining a net-short exposure.

  • [By ]

    Citigroup Inc. (C)  , a rival Wall Street bank, said in a separate report Friday that first-quarter profit jumped 13%, also fueled by growth in trading revenue. Meanwhile, San Francisco-based Wells Fargo & Co. (WFC) , struggling to recover from a series of regulatory penalties over allegedly aggressive sales practices, posted a 5.5% profit increase on a preliminary basis, noting that legal costs might have to be revised higher pending discussions with regulators over as much as $1 billion of new penalties related to auto insurance and mortgage-related violations. Bank of America Corp. (BAC) , Goldman Sachs Group Inc. (GS) and Morgan Stanley (MS) are all scheduled to post results next week.

  • [By The Ticker Tape]

    Lined up for tomorrow are Bank of America Corp(NYSE: BAC), JPMorgan Chase & Co. (NYSE: JPM), and Wells Fargo & Co (NYSE: WFC), and there’s plenty of enthusiasm going into the results. The financial sector overall appears to have been a big benefactor of what traders are calling the “Trump rally,” a market surge that began almost immediately after the November presidential elections. BAC shares have swelled some 35% since Nov. 8 to reach an eight-year high, while JPM shares are higher by nearly 29% after reaching record peaks. WFC is up by 20% after tapping an 18-month high.

Top 10 Blue Chip Stocks To Own For 2018: Xenon Pharmaceuticals Inc.(XENE)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Monday, our Under the Radar Moversnewsletter suggestedgoing long on small cap orphan biopharmaceutical stock Xenon Pharmaceuticals (NASDAQ: XENE):

  • [By Jim Robertson]

    Yesterday, our Under the Radar Moversnewsletter suggested going long on small cap biopharmaceutical stock Xenon Pharmaceuticals Inc (NASDAQ: XENE):

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 51 percent to $4.80 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 53 percent to $4.68 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

Top 10 Blue Chip Stocks To Own For 2018: United States Steel Corporation(X)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market finished in the red Wednesday, with very modest losses in most major benchmarks. Even the release of a broad outline of the Trump administration’s tax reform plan wasn’t enough to spur too much excitement among investors, as some worry that the plan’s focus on corporate taxes and balanced approach toward individual income tax reform might not resonate with the bulk of the American public. Moreover, bad news from some sectors of the market helped to dampen excitement from earlier in the week, and U.S. Steel (NYSE:X), Seagate Technology (NASDAQ:STX), and Dr Pepper Snapple Group (NYSE:DPS) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By Ben Levisohn]

    U.S. Steel (X) got a pop this morning, following China’s market. Since then, it’s been all downhill.

    Getty Images

    I’m not sure I can pinpoint a reason why. Base metals seemed to have a good day, with Comex Copper for April delivery having gained 2.7% to $2.675 per pound today, while nickel also gained.

    But U.S. Steel is getting killed, as are AK Steel (AKS), Steel Dynamics (STLD) and Nucor (NUE). Can we chalk it up to Paul Ryan’s comments that tax reform could take longer than health care reform, which also seems to be tanking the overall market?

    Whatever it is, here is Axiom Capital’s Gordon Johnson on why he’s worried about steel imports:

    As we have stated previously, we feel President Trumps administration will likely resort to countervailing duties/tariffs to penalize the countries it deems are cheating (not 201/301 actions). However, given roughly 88 countries import steel into the US, we question how effective this approach will prove as many countries will simply re-route steel to the countries who can ship into the US, ultimately allowing the steel to find its way to our shores.

    Shares of U.S. Steel have slumped 3.5% to $32.70 at 3:47 p.m. today, while AK Steel has tumbled 4.9% to $6.84, and Steel Dynamics has dropped 3.4% to $34.10, and Nucor is off 1.4% to $59.62.

  • [By Craig Jones]

    Pete Najarian noticed a big options volume in United States Steel Corporation (NYSE: X). He said that traders are betting that the stock is going lower after it had a huge run. He also believes that there is more room to the downside in United States Steel.

  • [By Lee Jackson]

    These companies also reported insider buying last week: Apache Corp. (NYSE: APA), Halliburton Co. (NYSE: HAL), Revlon Inc. (NYSE: REV), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and U.S. Steel Corp. (NYSE: X).

  • [By Merrick Weingarten]

    Steel stocks were up big on Tuesday ahead of the Department of Commerce hearing on the Section 232 probe. The DoC is set to come out with more details regarding the impact steel imports has on U.S. national security.

    Stock Movements
    United States Steel Corporation (NYSE: X): Up 5.27 percent. AK Steel Holding Corporation (NYSE: AKS): Up 9.55 percent. Nucor Corporation (NYSE: NUE): Up 3.54 percent. Steel Dynamics, Inc. (NASDAQ: STLD): Up 4.08 percent. Worthington Industries, Inc. (NYSE: WOR): Up 3.29 percent.
    Analyst Commentary

    A Jefferies research analyst suggested a high probability of the DoC institutes more incremental trade defense measures but noted most of the investigation remains unknown going into Wednesday.

  • [By Lisa Levin]

    United States Steel Corporation (NYSE: X) shares dropped 27 percent to $22.84. after the company reported surprise loss for its first quarter. U.S. Steel reported an adjusted loss of $0.83 per share and revenue of $2.73 billion.

Top 10 Blue Chip Stocks To Own For 2018: Oaktree Capital Group, LLC(OAK)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Oaktree Capital Group (OAK) is known for its contrarian approach with many of its products concentrating on distressed assets and turnaround situations.

  • [By Benzinga News Desk]

    President Donald Trump hinted he may intervene in the Justice Department’s Russia investigation, as a Senate panel advanced a measure to protect Special Counsel Robert Mueller: Link

    ECONOMIC DATA
    USA GDP (QoQ) for Q1 2.30% vs 2.00% Est; Prior 2.90%
    The University of Michigan's consumer confidence index for April is schedule for release at 10:00 a.m. ET.
    The Baker Hughes North American rig count report for the latest week will be released at 1:00 p.m. ET.
    Data on farm prices for the recent week will be released at 3:00 p.m. ET.
    ANALYST RATINGS
    Stifel upgraded Facebook (NASDAQ: FB) from Hold to Buy
    Morgan Stanley upgraded Acacia Communications (NASDAQ: ACIA) from Underweight to Equal-Weight
    Jefferies downgraded Sunoco (NYSE: SUN) from Hold to Underperform
    KBW downgraded Oaktree Capital (NYSE: OAK) from Outperform to Market Perform

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

Top 10 Blue Chip Stocks To Own For 2018: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on The Blackstone Group (BX) , Nvidia  (NVDA) , Amgen (AMGN) , Regeneron Pharmaceuticals (REGN) , Hasbro (HAS) and Waste Management (WM) .

  • [By ]

    For example, if you buy 100 shares of theNasdaq100ETF(NYSE: QQQ), you’re theoretically buying 11.9 shares of Apple (NASDAQ: AAPL)… 7.7 shares of Facebook (NASDAQ: FB)… 1.8 shares ofAmgen(NASDAQ: AMGN)… 2.6 shares of Comcast (NASDAQ: CMCSA)… and even smaller amounts of about 95 different companies.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

Top 10 Blue Chip Stocks To Own For 2018: Genesis Energy, L.P.(GEL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Breaking news

    Lennar Corporation (NYSE: LEN) reported better-than-expected profit for its first quarter on Tuesday.
    General Mills, Inc. (NYSE: GIS) reported upbeat earnings for its fiscal third quarter, while sales missed estimates.
    Genesis Energy, L.P. (NYSE: GEL) disclosed that it has priced its public offering of 4 million common units for gross proceeds of $124 million.
    South State Corporation (NASDAQ: SSB) reported that it has increased its buyback plan from 250,000 shares to 1 million shares.

  • [By ]

    Genesis Energy LP (NYSE: GEL)
    Billing itself as a “growth-oriented master limited partnership,” GEL concentrates its efforts on providing services around and within refineries primarily located on the Gulf Coast. Management is committed to logical double-digit growth as well as strengthening its distribution coverage. At $20.80 per unit, GEL yields 11.8% and trades at a nearly 40% discount to its 52-week high.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
    Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
    American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
    Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
    LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
    V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
    Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
    Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
    Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
    Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
    Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
    ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
    Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
    Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
    Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
    Genesis Energy, L.P